Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis
- 作者: Avdeeva A1, Aleksandrova E1, Novikov A1, Cherkasova M1, Panasiuk E1, Nasonov E1
-
隶属关系:
- НИИ ревматологии РАМН, Москва
- 期: 卷 85, 编号 5 (2013)
- 页面: 24-29
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31259
- ID: 31259
如何引用文章
全文:
详细
作者简介
A Avdeeva
НИИ ревматологии РАМН, Москва115522 Москва, Каширское шоссе, д. 34а
E Aleksandrova
НИИ ревматологии РАМН, Москва
A Novikov
НИИ ревматологии РАМН, Москва
M Cherkasova
НИИ ревматологии РАМН, Москва
E Panasiuk
НИИ ревматологии РАМН, Москва
E Nasonov
НИИ ревматологии РАМН, Москва
参考
- Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М: ГЭОТАР-Медиа 2008; 290-331.
- McInnes I., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7 (6): 429-442.
- Burrage P., Mix K., Brinckerhoff C. Matrix metalloproteinases: role in arthritis. Front Biosci 2006; 11: 529-543.
- Murphy G., Knauper V., Atkinson S. et al. Matrix metalloproteinases in arthritic disease. Arthritis Res 2002; 4 (Suppl 3): 39-49.
- Flannery C. MMPs and ADAMTSs: functional studies. Front Biosci 2006; 11: 44-569.
- Ribbens C., Andre B., Kaye O. et al. Synovial fluid matrix metalloproteinase 3 levels are increased in inflammatory arthritis whether erosive or not. Rheumatology 2000; 39: 1357-1365.
- Bonassar L., Frank E., Murray J. et al. Grodzinsky: Changes in cartilage composition and physical properties due to stromelysin degradation. Arthritis Rheum 1995; 38 (2): 173-183.
- Unemori E., Bair M., Bauer E. et al. Amento: Stromelysin expression regulates collagenase activation in human fibroblasts. Dissociable control of two metalloproteinases by interferon-gamma. J Biol Chem 1991; 266 (34): 23 477-23 482.
- Ribbens C., Porras M., Franchimont N. et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002; 61: 161-166.
- Kobayashi A., Naito S., Enomoto H. et al. Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med 2007; 131: 563-570.
- Posthumus M., Limburg P., Westra J. et al. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. J Rheumatol 2002; 29: 883-889.
- Yokoe I., Nishio S., Sato H., Kobayashi H. Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks. Mod Rheumatol 2011; 21: 710-714.
- Garnero P., Thompson E., Woodworth T., Smolen J. Rapid and Sustained Improvement in Bone and Cartilage Turnover Markers With the Anti-Interleukin-6 Receptor Inhibitor Tocilizumab Plus Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate. Arthritis Rheum 2010; 62: 33-43.
- Gibbons L., Hyrich K. Biologic therapy for rheumatoid arthritis. Clinical efficacy and predictors of response. Blodrugs 2009; 23: 111-124.
- Catrina A., Lampa J., Ernestam S. et al. Anti-tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 2002; 41: 484-489.
- Crnkic M., Mânsson B., Larsson L. et al. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther 2003; 5: R181-R185.
- Young-Min S., Cawston T., Marshall N. et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007; 56: 3236-3247.
- Green M., Gough A., Devlin J. et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 2003; 42: 83-88.
- Mamehara A., Sugimoto T., Sudiyama D. et al. Serum matrix Metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatiс drugs. Kobe J Med Sci 2010; 56: 98-107.
- Nishimoto N., Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol 2008; 181: 151-160.
- Насонов Е.Л. Новые подходы к фармакотерапии ревматоидного артрита: перспективы применения тоцилизумаба (моноклональные антитела к рецептору интерлейкина-6). Тер арх 2010; 5: 64-71.
- Oldfield V., Dhillon S., Plosker G.L. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009; 69: 609-632.
- Frey N., Grange S., Woodworth T. Relationship between serum concentration of the interleukin-6 receptor inhibitor tocilizumab and C-reactive protein reduction in RA patients: 6 months data from a phase 3 study. Arthritis Rheum 2007; 56 (Suppl. 9): 148-149.
- Choy E.H., Isenberg D.A., Garrood T. et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002; 46: 3143-3150.
- Nishimoto N., Terao K., Mima T. et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112: 3959-3964.
- Насонов Е.Л., Панасюк Е.Ю., Булдаков С.Г. и др. Эффективность и безопасность тоцилизумаба при ревматоидном артрите (промежуточные результаты российского многоцентрового исследования). Науч-практ ревматол 2009; 2: 21-29.
- Александрова Е.Н., Панасюк Е.Ю., Авдеева А.С. и др. Динамика лабораторных биомаркеров у больных ревматоидным артритом на фоне терапии тоцилизумабом. Науч-практ ревматол 2011; 3: 14-19.
- Панасюк Е.Ю., Амирджанова В.Н., Александрова Е.Н. и др. Быстрый эффект тоцилизумаба при ревматоидном артрите. Науч-практ ревматол 2011; 4: 11-16.
- Fransen J., Stucki G., van Reil P.L.C.M. Rheumatoid arthritis measures Arthritis Rheum 2003; 49: 214-224.
- Smolen J., Breedveld F.,Schiff M, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003; 42: 244-257.
- Shaver T.S., Anderson J.D., Weidensaul D.N. et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol 2008; 35: 1015-1022.
- Nishimoto N. Drug free remission after cessation of Actemra monotherapy (DREAM study) Ann Rheum Dis 2010; 69 (Suppl 3): 98.
- Kaneko A., Kida D., Saito K. et al. Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI. Rheumatology Int. doi: 10.1007/s00296-011-2256-5
- Urata Y., Uesato R., Tanaka D. et al. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. Ann Rheum Dis 2012; 71: 534-540.
- Bang H., Lüthke K., Gauliard A. et al. Mutated citrullinated vimentin as a candidate autoantigen for diagnosis and monitoring of disease activity in rheumatoid arthritis. Ann Rheum Dis 2006; 65 (Suppl II): 144.
- Roland P., Mignot S., Bruns A. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther 2008; 10: 142.
- Vizioli C., Viana V., Ribeiro A. Auto-antibody titers for monitoring rituximab therapy in rheumatoid arthritis Ann Rheum Dis 2012; 71(Suppl 3): 667.
- Hama M., Uehara T., Takase K. et al. Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab-preliminary data. Mod Rheumatol 2012; 32 (5): 1327-1333.